At LongeVC, we believe in supporting technologies that redefine the boundaries of science and open new frontiers for healthcare and biotechnology. Our recent partnership with Glyphic Bio reflects this commitment, as the company advances the field of protein sequencing with a single-molecule technology that could transform the proteomics research market and beyond.
Proteins, the functional drivers of biological systems, represent one of the most challenging frontiers in ‘omics.’ Currently, the gold standard for sequencing proteins is the mass spectrometry method, but it requires complex sample preparation and has many limitations, like needing a high concentration of purified protein material, which limits insights into low abundance proteins and complex mixes of proteins. Glyphic’s method would allow to analyze the sequence of every single protein in a complex protein mixture, enabling breakthroughs in understanding of life’s proteomes, and the translation of such insights into therapeutics and diagnostics.
Glyphic Bio’s technology not only has strong potential within proteomics—a market poised for substantial growth—but also holds applications across other rapidly evolving sectors. By unlocking access to previously unattainable biological insights, Glyphic sets a new standard for protein sequencing technology.
We look forward to seeing Glyphic Bio’s innovative solutions– their work has the potential to not only reshape the proteomics landscape but also open new opportunities in fields ranging from drug discovery to diagnostics.
To learn more about Glyphic Bio, visit their website here.
Proteins, the functional drivers of biological systems, represent one of the most challenging frontiers in ‘omics.’ Currently, the gold standard for sequencing proteins is the mass spectrometry method, but it requires complex sample preparation and has many limitations, like needing a high concentration of purified protein material, which limits insights into low abundance proteins and complex mixes of proteins. Glyphic’s method would allow to analyze the sequence of every single protein in a complex protein mixture, enabling breakthroughs in understanding of life’s proteomes, and the translation of such insights into therapeutics and diagnostics.
Glyphic Bio’s technology not only has strong potential within proteomics—a market poised for substantial growth—but also holds applications across other rapidly evolving sectors. By unlocking access to previously unattainable biological insights, Glyphic sets a new standard for protein sequencing technology.
We look forward to seeing Glyphic Bio’s innovative solutions– their work has the potential to not only reshape the proteomics landscape but also open new opportunities in fields ranging from drug discovery to diagnostics.
To learn more about Glyphic Bio, visit their website here.